Goldman Sachs raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $157 from $141 and keeps a Buy rating on the shares. Rhythm reported positive topline results from the Phase 2 study of setmelanotide in Prader-Willi Syndrome which demonstrated encouraging and consistent reductions in both BMI and hyperphagia across patients, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals price target raised to $141 from $114 at Canaccord
- Rhythm Pharmaceuticals price target raised to $167 from $141 at Citizens
- Palatin initiated with a Buy at LaidlawRhythm Pharmaceuticals
- Promising Phase 2 Results for Rhythm Pharmaceuticals’ Setmelanotide in Prader-Willi Syndrome Boost Buy Rating
- Rhythm Pharmaceuticals price target raised to $150 from $129 at Morgan Stanley